Showing results (2201-2210 of 2,371) with videos related to

Sort By:
Pageof 238
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 20, 2010
Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screeningDaniel M Rotroff, Barbara A Wetmore, David J Dix, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
Influenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018-May 2019Brendan Flannery, Jessie R Chung, Crystal Holiday, et al.
Infection Control and Hospital Epidemiology|February 14, 2014
Contact precautions: more is not necessarily betterSorabh Dhar, Dror Marchaim, Ryan Tansek, et al.
Infection Control and Hospital Epidemiology|November 13, 2012
Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycinTheresa Judge, Jason M Pogue, Dror Marchaim, et al.
Genes and Immunity|January 24, 2024
An immunogenomic exome landscape of triple positive primary antiphospholipid patientsA Guffroy, L Jacquel, Y Seeleuthner, et al.
Medrxiv : the Preprint Server for Health Sciences|October 1, 2025
Multiplex serology reveals age-specific immunodynamics of endemic respiratory pathogens in the wake of the COVID-19 pandemicSamantha J Bents, Emily T Martin, Terry Steven-Ayers, et al.
La Revue De Medecine Interne|September 21, 2023
French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and childrenZ Amoura, B Bader-Meunier, C Bal Dit Sollier, et al.
Nature Communications|May 24, 2017
Airborne observations reveal elevational gradient in tropical forest isoprene emissionsDasa Gu, Alex B Guenther, John E Shilling, et al.
Cephalalgia : an International Journal of Headache|May 3, 2021
Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trialTodd J Schwedt, Soma Sahai-Srivastava, Natalia Murinova, et al.
Leukemia|May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyA J Jakubowiak, D S Siegel, T Martin, et al.
Pageof 238